Cargando…

Health-related quality of life of multiple sclerosis patients: a European multi-country study

BACKGROUND: Inconsistent use of generic and disease-specific health-related quality of life (HRQOL) instruments in multiple sclerosis (MS) studies limits cross-country comparability. The objectives: 1) investigate real-world HRQOL of MS patients using both generic and disease-specific HRQOL instrume...

Descripción completa

Detalles Bibliográficos
Autores principales: Visser, Laurenske A., Louapre, Celine, Uyl-de Groot, Carin A., Redekop, William K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980344/
https://www.ncbi.nlm.nih.gov/pubmed/33743785
http://dx.doi.org/10.1186/s13690-021-00561-z
_version_ 1783667427741007872
author Visser, Laurenske A.
Louapre, Celine
Uyl-de Groot, Carin A.
Redekop, William K.
author_facet Visser, Laurenske A.
Louapre, Celine
Uyl-de Groot, Carin A.
Redekop, William K.
author_sort Visser, Laurenske A.
collection PubMed
description BACKGROUND: Inconsistent use of generic and disease-specific health-related quality of life (HRQOL) instruments in multiple sclerosis (MS) studies limits cross-country comparability. The objectives: 1) investigate real-world HRQOL of MS patients using both generic and disease-specific HRQOL instruments in the Netherlands, France, the United Kingdom, Spain, Germany and Italy; 2) compare HRQOL among these countries; 3) determine factors associated with HRQOL. METHODS: A cross-sectional, observational online web-based survey amongst MS patients was conducted in June–October 2019. Patient demographics, clinical characteristics, and two HRQOL instruments: the generic EuroQOL (EQ-5D-5L) and disease-related Multiple Sclerosis Quality of Life (MSQOL)-54, an extension of the generic Short Form-36 (SF-36) was collected. Health utility scores were calculated using country-specific value sets. Mean differences in HRQOL were analysed and predictors of HRQOL were explored in regression analyses. RESULTS: In total 182 patients were included (the Netherlands: n = 88; France: n = 58; the United Kingdom: n = 15; Spain: n = 10; living elsewhere: n = 11). Mean MSQOL-54 physical and mental composite scores (42.5, SD:17.2; 58.3, SD:21.5) were lower, whereas the SF-36 physical and mental composite scores (46.8, SD:22.6; 53.1, SD:22.5) were higher than reported in previous clinical trials. The mean EQ-5D utility was 0.65 (SD:0.26). Cross-country differences in HRQOL were found. A common predictor of HRQOL was disability status and primary progressive MS. CONCLUSIONS: The effects of MS on HRQOL in real-world patients may be underestimated. Combined use of generic and disease-specific HRQOL instruments enhance the understanding of the health needs of MS patients. Consequent use of the same instruments in clinical trials and observational studies improves cross-country comparability of HRQOL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13690-021-00561-z.
format Online
Article
Text
id pubmed-7980344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79803442021-03-22 Health-related quality of life of multiple sclerosis patients: a European multi-country study Visser, Laurenske A. Louapre, Celine Uyl-de Groot, Carin A. Redekop, William K. Arch Public Health Research BACKGROUND: Inconsistent use of generic and disease-specific health-related quality of life (HRQOL) instruments in multiple sclerosis (MS) studies limits cross-country comparability. The objectives: 1) investigate real-world HRQOL of MS patients using both generic and disease-specific HRQOL instruments in the Netherlands, France, the United Kingdom, Spain, Germany and Italy; 2) compare HRQOL among these countries; 3) determine factors associated with HRQOL. METHODS: A cross-sectional, observational online web-based survey amongst MS patients was conducted in June–October 2019. Patient demographics, clinical characteristics, and two HRQOL instruments: the generic EuroQOL (EQ-5D-5L) and disease-related Multiple Sclerosis Quality of Life (MSQOL)-54, an extension of the generic Short Form-36 (SF-36) was collected. Health utility scores were calculated using country-specific value sets. Mean differences in HRQOL were analysed and predictors of HRQOL were explored in regression analyses. RESULTS: In total 182 patients were included (the Netherlands: n = 88; France: n = 58; the United Kingdom: n = 15; Spain: n = 10; living elsewhere: n = 11). Mean MSQOL-54 physical and mental composite scores (42.5, SD:17.2; 58.3, SD:21.5) were lower, whereas the SF-36 physical and mental composite scores (46.8, SD:22.6; 53.1, SD:22.5) were higher than reported in previous clinical trials. The mean EQ-5D utility was 0.65 (SD:0.26). Cross-country differences in HRQOL were found. A common predictor of HRQOL was disability status and primary progressive MS. CONCLUSIONS: The effects of MS on HRQOL in real-world patients may be underestimated. Combined use of generic and disease-specific HRQOL instruments enhance the understanding of the health needs of MS patients. Consequent use of the same instruments in clinical trials and observational studies improves cross-country comparability of HRQOL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13690-021-00561-z. BioMed Central 2021-03-20 /pmc/articles/PMC7980344/ /pubmed/33743785 http://dx.doi.org/10.1186/s13690-021-00561-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Visser, Laurenske A.
Louapre, Celine
Uyl-de Groot, Carin A.
Redekop, William K.
Health-related quality of life of multiple sclerosis patients: a European multi-country study
title Health-related quality of life of multiple sclerosis patients: a European multi-country study
title_full Health-related quality of life of multiple sclerosis patients: a European multi-country study
title_fullStr Health-related quality of life of multiple sclerosis patients: a European multi-country study
title_full_unstemmed Health-related quality of life of multiple sclerosis patients: a European multi-country study
title_short Health-related quality of life of multiple sclerosis patients: a European multi-country study
title_sort health-related quality of life of multiple sclerosis patients: a european multi-country study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980344/
https://www.ncbi.nlm.nih.gov/pubmed/33743785
http://dx.doi.org/10.1186/s13690-021-00561-z
work_keys_str_mv AT visserlaurenskea healthrelatedqualityoflifeofmultiplesclerosispatientsaeuropeanmulticountrystudy
AT louapreceline healthrelatedqualityoflifeofmultiplesclerosispatientsaeuropeanmulticountrystudy
AT uyldegrootcarina healthrelatedqualityoflifeofmultiplesclerosispatientsaeuropeanmulticountrystudy
AT redekopwilliamk healthrelatedqualityoflifeofmultiplesclerosispatientsaeuropeanmulticountrystudy